US6022866A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of hyaluronic acid and forms to prevent arterial restenosis
Assignee: NORPHARMCO Inc
•
Filing: 1993-09-22
•
Granted: 2000-02-08
•
Expires: 2013-09-22
Abstract
Abstract PCT No. PCT/CA93/00388 Sec. 371 Date Mar. 24, 1995 Sec. 102(e) Date Mar. 24, 1995 PCT Filed Sep. 22, 1993 PCT Pub. No. WO94/07505 PCT Pub. Date Apr. 14, 1994A method is provided of inhibiting the narrowing of the vascular tubular walls of an animal by the proliferation of endothelial cells in the area of trauma after the vascular tubular walls have been traumatized, the method comprising the administration of a therapeutically effective non-toxic amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof to the animal to inhibit the narrowing of the vascular tubular walls by the proliferation of endothelial cells into the area of trauma.
Inventors
- 👤 Rudolf Edgar Falk
- 👤 Samuel Simon Asculai
- 👤 Eva Anne Turley
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 17:04
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K31/00; A61K31/185; A61K31/19; A61K31/192; A61K31/195; A61K31/196; A61K31/33; A61K31/395; A61K31/40; A61K31/403; A61K31/404; A61K31/405; A61K31/407; A61K31/435; A61K31/44; A61K31/455; A61K31/495; A61K31/50; A61K31/503; A61K31/54; A61K31/5415; A61K31/60; A61K31/612; A61K31/616; A61K31/70; A61K31/715; A61K31/726; A61K31/728; A61K45/00; A61K45/06; A61K47/00; A61K47/30; A61K47/36; A61K47/06; A61K47/08; A61K47/10
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
163 words
A method of inhibiting the narrowing of the vascular tubular walls of an animal by the proliferation of endothelial cells in the area of trauma after the vascular tubular walls have been traumatized, the method comprising the administration of a therapeutically effective non-toxic amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof, and a therapeutically effective amount of an agent selected from the group consisting of a non-steroidal anti-inflammatory drug (NSAID), Vitamin C, a stenosis inhibiting drug, an anti-oxidant, a free radical scavenger and combinations thereof for enhancing the effect of the form of hyaluronic acid administered in the inhibition of the narrowing of the tubular walls to the animal to inhibit the narrowing of the vascular tubular walls by the proliferation of the endothelial cells on the area of trauma, and wherein the molecular weight of the form of hyaluronic acid is less than 750,000 daltons and greater than 150,000 daltons.
Claim 2
Independent Claim
163 words
A method of inhibiting the narrowing of the vascular tubular walls of an animal by the proliferation of endothelial cells in the area of trauma after the vascular tubular walls have been traumatized, the method comprising the administration of a therapeutically effective non-toxic amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof, and a therapeutically effective amount of an agent selected from the group consisting of a non-steroidal anti-inflammatory drug (NSAID), Vitamin C, a stenosis inhibiting drug, an anti-oxidant, a free radical scavenger and combinations thereof for enhancing the effect of the form of hyaluronic acid administered in the inhibition of the narrowing of the tubular walls to the animal to inhibit the narrowing of the vascular tubular walls by the proliferation of the endothelial cells on the area of trauma, and wherein the molecular weight of the form of hyaluronic acid is less than 750,000 daltons and greater than 150,000 daltons.
Claim 3
Dependent Claim
25 words
The method of claim 1, wherein the molecular weight of the form of hyaluronic acid is greater than 150,000 daltons and less than 225,000 daltons.
Claim 4
Dependent Claim
30 words
The method of claim 2, wherein the tubular walls are arteries which have been subjected to balloon angioplasty and the administration takes places before, during or after the balloon angioplasty.
Claim 5
Dependent Claim
22 words
The method of claim 3 wherein the amount of the form of hyaluronic acid administered is between 10 mg and 3000 mg.
Claim 6
Independent Claim
156 words
A method of inhibiting arterial restenosis of the arterial wall by the proliferation of endothelial cells on the inner wall of the artery after balloon angioplasty in a human, the method comprising the administration of a therapeutically effective non-toxic amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid, pharmaceutically acceptable salts thereof and combinations thereof, a therapeutically effective amount of an agent selected from the group consisting of a non-steroidal anti-inflammatory drug (NSAID), Vitamin C, a stenosis inhibiting drug, an anti-oxidant, a free radical scavenger and combinations thereof for enhancing the effect of the form of hyaluronic acid administered in the inhibition of the narrowing of the tubular walls to the human to inhibit arterial restenosis by the proliferation of endothelial cells on the inner wall of the artery, and wherein the molecular weight of the form of hyaluronic acid is less than 750,000 daltons and greater than 150,000 daltons.
Claim 7
Independent Claim
156 words
A method of inhibiting arterial restenosis of the arterial wall by the proliferation of endothelial cells on the inner wall of the artery after balloon angioplasty in a human, the method comprising the administration of a therapeutically effective non-toxic amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid, pharmaceutically acceptable salts thereof and combinations thereof, a therapeutically effective amount of an agent selected from the group consisting of a non-steroidal anti-inflammatory drug (NSAID), Vitamin C, a stenosis inhibiting drug, an anti-oxidant, a free radical scavenger and combinations thereof for enhancing the effect of the form of hyaluronic acid administered in the inhibition of the narrowing of the tubular walls to the human to inhibit arterial restenosis by the proliferation of endothelial cells on the inner wall of the artery, and wherein the molecular weight of the form of hyaluronic acid is less than 750,000 daltons and greater than 150,000 daltons.
Claim 8
Dependent Claim
25 words
The method of claim 5, wherein the molecular weight of the form of hyaluronic acid is greater than 150,000 daltons and less than 225,000 daltons.
Claim 9
Dependent Claim
22 words
The method of claim 5, wherein the amount of the form of hyaluronic acid administered is between 10 mg and 3000 mg.
Claim 10
Dependent Claim
24 words
The method of claim 5, 6, or 7 wherein the form of hyaluronic acid is administered prior to, during or after the balloon angioplasty.
Claim 11
Dependent Claim
23 words
The method of claim 1, 2, 3, 4, 5, 6, or 7 wherein the form of hyaluronic acid is sodium hyaluronate administered intravenously.
Claim 12
Dependent Claim
35 words
The method of claim 1, 2, 3, 4, 5, 6 or 7 wherein the therapeutically effective amount of the combination of the form of hyaluronic acid and agent are in the form for intravenous administration.
Claim 13
Independent Claim
127 words
A method of inhibiting arterial restenosis of the arterial wall by the proliferation of endothelial cells on the area of trauma after balloon angioplasty, the method comprising the administration of a therapeutically effective non-toxic amount of hyaluronic acid and/or pharmaceutically acceptable salts thereof whose molecular weight is less than 750,000 daltons and greater than 150,000 daltons, and a therapeutically effective amount of an agent selected from the group consisting of a non-steroidal anti-inflammatory drug (NSAID), Vitamin C, a stenosis inhibiting drug, an anti-oxidant, a free radical scavenger and combinations thereof for enhancing the effect of the form of hyaluronic acid administered in the inhibition of the narrowing of the tubular walls to inhibit arterial restenosis by the proliferation of the endothelial cells on the area of trauma.
Claim 14
Independent Claim
127 words
A method of inhibiting arterial restenosis of the arterial wall by the proliferation of endothelial cells on the area of trauma after balloon angioplasty, the method comprising the administration of a therapeutically effective non-toxic amount of hyaluronic acid and/or pharmaceutically acceptable salts thereof whose molecular weight is less than 750,000 daltons and greater than 150,000 daltons, and a therapeutically effective amount of an agent selected from the group consisting of a non-steroidal anti-inflammatory drug (NSAID), Vitamin C, a stenosis inhibiting drug, an anti-oxidant, a free radical scavenger and combinations thereof for enhancing the effect of the form of hyaluronic acid administered in the inhibition of the narrowing of the tubular walls to inhibit arterial restenosis by the proliferation of the endothelial cells on the area of trauma.
Claim 15
Dependent Claim
23 words
The method of claim 11, wherein the amount of the hyaluronic acid and/or salts thereof administered is between 10 mg and 3000 mg.
Claim 16
Dependent Claim
25 words
The method of claim 12 wherein the NSAID is an effective dosage amount and the amount of hyaluronic acid and salts thereof exceeds 200 mg.
Claim 17
Dependent Claim
230 words
A pharmaceutical composition comprising together with diluents, adjuvants and other pharmaceutical carriers as desired; (1) an effective amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid, pharmaceutically acceptable salts thereof, and combinations thereof, and (2) an agent selected from the group consisting of a stenosis inhibiting drug, a non-steroidal anti-inflammatory drug (NSAID), Vitamin C, a free radical scavenger, and an anti-oxidant and combinations thereof, for inhibiting the narrowing of the vascular tubular walls of an animal by the build-up of endothelial cells on the vascular tubular walls after the tubular walls have been traumatized, the composition being characterized by an effective non-toxic amount of the form of hyaluronic acid being incorporated into the composition together with a therapeutically effective amount of agent (2), to inhibit tubular wall narrowing by the build-up of endothelial cells on the vascular tubular walls, wherein the effective amount of component (1) is between 10 mg to 3000 mg to prevent the narrowing of the tubular walls of the animal by the build-up of endothelial cells on the vascular tubular walls and wherein component (2) enhances the effect of component (1) in the prevention of the narrowing of the tubular walls by the build-up of endothelial cells on the vascular tubular walls, and wherein the molecular weight of component (1) is less than 750,000 daltons and greater than 150,000 daltons.
Claim 18
Dependent Claim
230 words
A pharmaceutical composition comprising together with diluents, adjuvants and other pharmaceutical carriers as desired; (1) an effective amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid, pharmaceutically acceptable salts thereof, and combinations thereof, and (2) an agent selected from the group consisting of a stenosis inhibiting drug, a non-steroidal anti-inflammatory drug (NSAID), Vitamin C, a free radical scavenger, and an anti-oxidant and combinations thereof, for inhibiting the narrowing of the vascular tubular walls of an animal by the build-up of endothelial cells on the vascular tubular walls after the tubular walls have been traumatized, the composition being characterized by an effective non-toxic amount of the form of hyaluronic acid being incorporated into the composition together with a therapeutically effective amount of agent (2), to inhibit tubular wall narrowing by the build-up of endothelial cells on the vascular tubular walls, wherein the effective amount of component (1) is between 10 mg to 3000 mg to prevent the narrowing of the tubular walls of the animal by the build-up of endothelial cells on the vascular tubular walls and wherein component (2) enhances the effect of component (1) in the prevention of the narrowing of the tubular walls by the build-up of endothelial cells on the vascular tubular walls, and wherein the molecular weight of component (1) is less than 750,000 daltons and greater than 150,000 daltons.
Claim 19
Dependent Claim
22 words
The composition of claim 14 wherein the molecular weight of component (1) is greater than 150,000 daltons and less than 225,000 daltons.
Claim 20
Dependent Claim
17 words
The composition of claim 14 or 15 wherein component (1) comprises a stenosis-inhibiting drug and an NSAID.
Claim 21
Dependent Claim
19 words
The composition according to claim 14 or 15 in injectable or intravenous form and component (1) is sodium hyaluronate.
Claim 22
Dependent Claim
21 words
The method of claim 14 or 15, wherein component (1) is utilized at a dose between 10 mg to 1000 mg.
Claim 23
Dependent Claim
18 words
The composition of claim 14 or 15, wherein the amount of component (1) is greater than 200 mg.
Claim 24
Dependent Claim
20 words
The composition of claim 19 wherein the pharmaceutical composition is for inhibition of arterial restenosis after balloon angioplasty in humans.
References Cited (Backward Citations)
US2583096A
Cited
US3436454A
Cited
US3887703A
Cited
GB1283892A
Cited
US4141973A
Cited
US4141973B1
Cited
US4272522A
Cited
GB2099826A
Cited
JPS57183707A
Cited
AU3080684A
Cited
CA1240929A
Cited
EP0138572A2
Cited
CA1205031A
Cited
US4970298A
Cited
US4716224A
Cited
US4711780A
Cited
JPS6117A
Cited
EP0179442A2
Cited
US4636524A
Cited
US4582865A
Cited
US4814176A
Cited
EP0197718A2
Cited
US4736024A
Cited
US4801619A
Cited
JPS61233622A
Cited
US4725585A
Cited
US4755544A
Cited
US4707354A
Cited
US4851521A
Cited
US4965353A
Cited
EP0216453A2
Cited
EP0208623A2
Cited
US4937254B1
Cited
US4937254A
Cited
EP0224987A2
Cited
JPS6345223A
Cited
US4840941A
Cited
EP0240098A2
Cited
US4808576A
Cited
AU7211787A
Cited
US4946870A
Cited
US4853226A
Cited
EP0265116A2
Cited
US4957744A
Cited
EP0270317A2
Cited
EP0287210A2
Cited
WO1988007060A1
Cited
EP0285357A2
Cited
US4795741A
Cited
EP0296740A2
Cited
EP0295092A2
Cited
AU1745988A
Cited
WO1989007932A1
Cited
JPH01287041A
Cited
US5032679A
Cited
EP0378852A1
Cited
WO1991004058A2
Cited
US5116864A
Cited
US5326757A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2003-02-07 | 2003-08-09 | 2004-02-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2007-02-07 | 2007-08-09 | 2008-02-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2011-02-07 | 2011-08-09 | 2012-02-08 | $7700.00 | Window Closed / Lapsed |